Smith & Howard Wealth Management LLC Has $259,000 Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Smith & Howard Wealth Management LLC reduced its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 17.5% during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 419 shares of the medical research company’s stock after selling 89 shares during the period. Smith & Howard Wealth Management LLC’s holdings in Thermo Fisher Scientific were worth $259,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in TMO. Convergence Financial LLC lifted its stake in Thermo Fisher Scientific by 30.8% in the 3rd quarter. Convergence Financial LLC now owns 2,942 shares of the medical research company’s stock valued at $1,820,000 after acquiring an additional 692 shares in the last quarter. Elwood & Goetz Wealth Advisory Group LLC bought a new stake in shares of Thermo Fisher Scientific in the third quarter worth $536,000. Joel Isaacson & Co. LLC grew its position in Thermo Fisher Scientific by 2.8% in the third quarter. Joel Isaacson & Co. LLC now owns 2,798 shares of the medical research company’s stock valued at $1,731,000 after purchasing an additional 77 shares in the last quarter. Lake Street Advisors Group LLC increased its stake in Thermo Fisher Scientific by 0.7% in the 3rd quarter. Lake Street Advisors Group LLC now owns 4,200 shares of the medical research company’s stock valued at $2,600,000 after buying an additional 28 shares during the last quarter. Finally, Blackston Financial Advisory Group LLC boosted its stake in shares of Thermo Fisher Scientific by 72.6% during the 3rd quarter. Blackston Financial Advisory Group LLC now owns 972 shares of the medical research company’s stock worth $601,000 after buying an additional 409 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on TMO shares. TD Cowen upped their target price on Thermo Fisher Scientific from $656.00 to $686.00 in a report on Tuesday. Wells Fargo & Company cut their price objective on Thermo Fisher Scientific from $670.00 to $660.00 and set an “overweight” rating for the company in a report on Thursday. Royal Bank of Canada dropped their price target on shares of Thermo Fisher Scientific from $767.00 to $718.00 and set an “outperform” rating on the stock in a research report on Thursday. Sanford C. Bernstein decreased their price objective on shares of Thermo Fisher Scientific from $625.00 to $620.00 and set a “market perform” rating for the company in a research report on Thursday. Finally, Morgan Stanley raised their target price on shares of Thermo Fisher Scientific from $655.00 to $680.00 and gave the company an “overweight” rating in a research note on Friday, September 20th. Five investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $649.33.

Insiders Place Their Bets

In other news, CEO Marc N. Casper sold 6,300 shares of the firm’s stock in a transaction that occurred on Monday, July 29th. The shares were sold at an average price of $602.09, for a total value of $3,793,167.00. Following the sale, the chief executive officer now directly owns 123,816 shares in the company, valued at approximately $74,548,375.44. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 6,300 shares of the firm’s stock in a transaction that occurred on Monday, July 29th. The shares were sold at an average price of $602.09, for a total value of $3,793,167.00. Following the sale, the chief executive officer now owns 123,816 shares in the company, valued at $74,548,375.44. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $617.21, for a total value of $6,172,100.00. Following the completion of the transaction, the chief executive officer now owns 123,816 shares of the company’s stock, valued at $76,420,473.36. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Trading Down 0.5 %

Shares of Thermo Fisher Scientific stock opened at $554.38 on Friday. The firm’s 50-day moving average price is $605.12 and its two-hundred day moving average price is $584.04. Thermo Fisher Scientific Inc. has a 12-month low of $420.21 and a 12-month high of $627.88. The company has a quick ratio of 1.37, a current ratio of 1.72 and a debt-to-equity ratio of 0.64. The company has a market capitalization of $211.77 billion, a price-to-earnings ratio of 34.39, a PEG ratio of 3.75 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, beating the consensus estimate of $5.25 by $0.03. Thermo Fisher Scientific had a net margin of 14.69% and a return on equity of 18.22%. The business had revenue of $10.60 billion during the quarter, compared to the consensus estimate of $10.63 billion. During the same period in the previous year, the business earned $5.69 earnings per share. The company’s revenue was up .2% on a year-over-year basis. On average, analysts forecast that Thermo Fisher Scientific Inc. will post 21.72 earnings per share for the current fiscal year.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.